New approach to presbyopia treament

Article

This is the first ESCRS congress for 9-month old company, Technolas, which was formed out of a joint venture between Bausch and Lomb's refractive surgery unit and 20/10 Perfect Vision. The new business was founded to innovate in excimer and femtosecond laser technologies, focusing primarily on the correction of presbyopia.

This is the first ESCRS congress for 9-month old company, Technolas, which was formed out of a joint venture between Bausch and Lomb's refractive surgery unit and 20/10 Perfect Vision. The new business was founded to innovate in excimer and femtosecond laser technologies, focusing primarily on the correction of presbyopia.

It promotes a comprehensive service and support structure to provide surgeons with training and applications support to adapt their clinics to service the developing presbyopia patient segment.

CCO Mike Riding explained: “The current LASIK market is very tough. The number of procedures being performed is stuck because 20 to 30 year olds don't have the cash for LASIK. The bread and butter market is very difficult.” Against this background he asks doctors to imagine a new procedure, a minimally invasive technique, that will service 40 to 60 year olds - the baby boomers.

Enter the new INTRACOR femtosecond laser procedure from Technolas. The INTRACOR technique provides flapless intrastromal correction using the FEMTEC femtosecond laser to reshape the cornea. Technolas says this can be achieved whilst still maintaining the integrity of the corneal surface.In addition to offering a solution for presbyopia the technique can also be used as a minimally invasive technique for hyperopia, myopia and astigmatism.

“We believe the market size will be several times larger than the current LASIK market,” said Riding. He explained that this is not just Technolas's view, but a growing belief that demand to treat presbyopia will continue to grow. Strong attendance at the wet labs run by the company at 20-minute intervals during this year's Congress could be evidence that he is right.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.